ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
(c)Trading Plans
During the quarter ended December 31, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
| Name | Title | Adoption or Termination Date | Plan End Date | Shares Vesting and Subject to Sell-To-Cover (1) | Other Shares Being Sold (Subject to Certain Conditions) |
|---|---|---|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | 12/22/2025 | 01/31/2030 | 1,871,805 | n/a |
| James Hamilton | Chief Medical Officer, Head of R&D | 12/02/2025 | 03/05/2027 | n/a | 44,000 |
(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.